nach oben

Journal of Cardiovascular Translational Research

Erschienen in:

01.04.2015

Concentrations of Highly Sensitive Cardiac Troponin-I Predict Poor Cardiovascular Outcomes and Adverse Remodeling in Chronic Heart Failure

verfasst von: Shweta R. Motiwala, Hanna K. Gaggin, Parul U. Gandhi, Arianna Belcher, Rory B. Weiner, Aaron L. Baggish, Jackie Szymonifka, James L. Januzzi Jr.

Erschienen in: Journal of Cardiovascular Translational Research | Ausgabe 3/2015

Einloggen, um Zugang zu erhalten

Abstract

Highly sensitive troponin (hsTn) assays may predict cardiovascular (CV) events and left ventricular (LV) remodeling in patients with heart failure (HF). In this study, 99 subjects with LV systolic dysfunction (LVSD) were followed 10 ± 3 months with serial measurement of hsTnI by a novel method. hsTnI was detectable in all subjects and was above the 99th percentile of a normal population in 56.7 %. Supramedian baseline hsTnI concentration was associated with higher-risk clinical features and shorter time-to-first event (p = 0.008). Across serial measurements, more time spent ≤10.9 pg/mL was associated with a lower CV event rate after adjustment (odds ratio (OR) = 0.81; p = 0.008); rising hsTnI also predicted progressive LV remodeling. In conclusion, hsTnI detected significant myocardial necrosis in a majority of patients with chronic HF due to LVSD and when measured serially, provided independent risk information for poor CV outcomes and deleterious LV remodeling.

Thygesen, K., Alpert, J. S., Jaffe, A. S., Simoons, M. L., Chaitman, B. R., White, H. D., Joint ESCAAHAWHFTFftUDoMI, Katus, H. A., Lindahl, B., Morrow, D. A., Clemmensen, P. M., Johanson, P., Hod, H., Underwood, R., Bax, J. J., Bonow, R. O., Pinto, F., Gibbons, R. J., Fox, K. A., Atar, D., Newby, L. K., Galvani, M., Hamm, C. W., Uretsky, B. F., Steg, P. G., Wijns, W., Bassand, J. P., Menasche, P., Ravkilde, J., Ohman, E. M., Antman, E. M., Wallentin, L. C., Armstrong, P. W., Simoons, M. L., Januzzi, J. L., Nieminen, M. S., Gheorghiade, M., Filippatos, G., Luepker, R. V., Fortmann, S. P., Rosamond, W. D., Levy, D., Wood, D., Smith, S. C., Hu, D., Lopez-Sendon, J. L., Robertson, R. M., Weaver, D., Tendera, M., Bove, A. A., Parkhomenko, A. N., Vasilieva, E. J., & Mendis, S. (2012). Third universal definition of myocardial infarction. Circulation, 126(16), 2020–2035. doi:10.1161/CIR.0b013e31826e1058.CrossRefPubMed

Januzzi, J. L., Jr., Filippatos, G., Nieminen, M., & Gheorghiade, M. (2012). Troponin elevation in patients with heart failure: on behalf of the third Universal Definition of Myocardial Infarction Global Task Force: Heart Failure Section. European Heart Journal, 33(18), 2265–2271. doi:10.1093/eurheartj/ehs191.CrossRefPubMed

Horwich, T. B., Patel, J., MacLellan, W. R., & Fonarow, G. C. (2003). Cardiac troponin I is associated with impaired hemodynamics, progressive left ventricular dysfunction, and increased mortality rates in advanced heart failure. Circulation, 108(7), 833–838. doi:10.1161/01.CIR.0000084543.79097.34.CrossRefPubMed

Wang, T. J., Wollert, K. C., Larson, M. G., Coglianese, E., McCabe, E. L., Cheng, S., Ho, J. E., Fradley, M. G., Ghorbani, A., Xanthakis, V., Kempf, T., Benjamin, E. J., Levy, D., Vasan, R. S., & Januzzi, J. L. (2012). Prognostic utility of novel biomarkers of cardiovascular stress: the Framingham Heart Study. Circulation, 126(13), 1596–1604. doi:10.1161/CIRCULATIONAHA.112.129437.CrossRefPubMed

de Lemos, J. A., Drazner, M. H., Omland, T., Ayers, C. R., Khera, A., Rohatgi, A., Hashim, I., Berry, J. D., Das, S. R., Morrow, D. A., & McGuire, D. K. (2010). Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population. JAMA, 304(22), 2503–2512. doi:10.1001/jama.2010.1768.CrossRefPubMed

Egstrup, M., Schou, M., Tuxen, C. D., Kistorp, C. N., Hildebrandt, P. R., Gustafsson, F., Faber, J., Goetze, J. P., & Gustafsson, I. (2012). Prediction of outcome by highly sensitive troponin T in outpatients with chronic systolic left ventricular heart failure. The American Journal of Cardiology, 110(4), 552–557. doi:10.1016/j.amjcard.2012.04.033.CrossRefPubMed

Masson, S., Anand, I., Favero, C., Barlera, S., Vago, T., Bertocchi, F., Maggioni, A. P., Tavazzi, L., Tognoni, G., Cohn, J. N., Latini, R., & Valsartan Heart Failure T, Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza Cardiaca-Heart Failure I. (2012). Serial measurement of cardiac troponin T using a highly sensitive assay in patients with chronic heart failure: data from 2 large randomized clinical trials. Circulation, 125(2), 280–288. doi:10.1161/CIRCULATIONAHA.111.044149.CrossRefPubMed

Gaggin, H. K., Szymonifka, J., Bhardwaj, A., Belcher, A., De Berardinis, B., Motiwala, S., Wang, T. J., & Januzzi, J. L., Jr. (2014). Head-to-head comparison of serial soluble ST2, growth differentiation factor-15, and highly-sensitive troponin T measurements in patients with chronic heart failure. JACC Heart Failure, 2(1), 65–72. doi:10.1016/j.jchf.2013.10.005.CrossRefPubMed

Januzzi, J. L., Jr., Rehman, S., Mohammed, A. A., Bhardwaj, A., Barajas, L., Barajas, J., Kim, H.-N., Baggish, A. L., Weiner, R. B., Chen, A. A., Marshall, J. E., Moore, S. A., Carlson, W. D., Lewis, G. D., Shin, J., Sullivan, D., Parks, K., Wang, T. J., Gregory, S., Uthamalingam, S., & Semigran, M. J. (2011). Use of amino-terminal pro-B type natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular systolic dysfunction. Journal of the American College of Cardiology, 58, 1881–1889.CrossRefPubMed

10.

Bhardwaj, A., Rehman, S. U., Mohammed, A., Baggish, A. L., Moore, S. A., & Januzzi, J. L., Jr. (2010). Design and methods of the pro-B type natriuretic peptide outpatient tailored chronic heart failure therapy (PROTECT) Study. American Heart Journal, 159(4), 532–538. doi:10.1016/j.ahj.2010.01.005. e531.CrossRefPubMed

11.

Lang, R. M., Bierig, M., Devereux, R. B., Flachskampf, F. A., Foster, E., Pellikka, P. A., Picard, M. H., Roman, M. J., Seward, J., Shanewise, J. S., Solomon, S. D., Spencer, K. T., Sutton, M. S., & Stewart, W. J. (2005). Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. Journal of the American Society of Echocardiography: Official Publication of the American Society of Echocardiography, 18(12), 1440–1463. doi:10.1016/j.echo.2005.10.005.CrossRef

12.

Gaggin, H. K., Truong, Q. A., Rehman, S. U., Mohammed, A. A., Bhardwaj, A., Parks, K. A., Sullivan, D. A., Chen-Tournoux, A., Moore, S. A., Richards, A. M., Troughton, R. W., Lainchbury, J. G., Weiner, R. B., Baggish, A. L., Semigran, M. J., & Januzzi, J. L., Jr. (2013). Characterization and prediction of natriuretic peptide "nonresponse" during heart failure management: results from the ProBNP Outpatient Tailored Chronic Heart Failure (PROTECT) and the NT-proBNP-Assisted Treatment to Lessen Serial Cardiac Readmissions and Death (BATTLESCARRED) study. Congestive Heart Failure, 19(3), 135–142. doi:10.1111/chf.12016.CrossRefPubMed

13.

Motiwala, S. R., Szymonifka, J., Belcher, A., Weiner, R. B., Baggish, A. L., Sluss, P., Gaggin, H. K., Bhardwaj, A., & Januzzi, J. L. (2013). Serial measurement of galectin-3 in patients with chronic heart failure: results from the ProBNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) study. European Journal of Heart Failure, 15(10), 1157–1163. doi:10.1093/eurjhf/hft075.CrossRefPubMed

14.

Miller, W. L., Hartman, K. A., Burritt, M. F., Grill, D. E., & Jaffe, A. S. (2009). Profiles of serial changes in cardiac troponin T concentrations and outcome in ambulatory patients with chronic heart failure. Journal of the American College of Cardiology, 54(18), 1715–1721. doi:10.1016/j.jacc.2009.07.025.CrossRefPubMed

Titel: Concentrations of Highly Sensitive Cardiac Troponin-I Predict Poor Cardiovascular Outcomes and Adverse Remodeling in Chronic Heart Failure
verfasst von: Shweta R. Motiwala
Hanna K. Gaggin
Parul U. Gandhi
Arianna Belcher
Rory B. Weiner
Aaron L. Baggish
Jackie Szymonifka
James L. Januzzi Jr.
Publikationsdatum: 01.04.2015
Verlag: Springer US
Erschienen in: Journal of Cardiovascular Translational Research / Ausgabe 3/2015
Print ISSN: 1937-5387
Elektronische ISSN: 1937-5395
DOI: https://doi.org/10.1007/s12265-015-9618-4

Neu im Fachgebiet Kardiologie

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Adipositas-Medikament auch gegen Schlafapnoe wirksam

24.04.2024 Adipositas Nachrichten

Der als Antidiabetikum sowie zum Gewichtsmanagement zugelassene Wirkstoff Tirzepatid hat in Studien bei adipösen Patienten auch schlafbezogene Atmungsstörungen deutlich reduziert, informiert der Hersteller in einer Vorab-Meldung zum Studienausgang.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2015

Absence of Cardiac Benefit with Early Combination ACE Inhibitor and Beta Blocker Treatment in mdx Mice

Enhancing the Predictive Power of Mutations in the C-Terminus of the KCNQ1-Encoded Kv7.1 Voltage-Gated Potassium Channel

Guidelines for the Isolation and Characterization of Murine Vascular Smooth Muscle Cells. A Report from the International Society of Cardiovascular Translational Research

BNP and Heart Failure: Preclinical and Clinical Trial Data